Corcept Therapeutics Incorporated (CORT)

Current ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Total current assets	US$ in thousands	471,602	466,978	560,846	503,367	458,636	431,527	432,588	528,179	498,707	452,402	427,555	388,220	381,387	401,900	411,270	409,624	524,247	463,493	438,333	391,836
Total current liabilities	US$ in thousands	140,773	126,216	100,750	97,202	104,505	121,873	93,059	25,216	81,588	53,068	54,038	57,244	6,908	44,757	45,402	40,601	10,554	43,048	42,243	36,005
Current ratio		3.35	3.70	5.57	5.18	4.39	3.54	4.65	20.95	6.11	8.52	7.91	6.78	55.21	8.98	9.06	10.09	49.67	10.77	10.38	10.88

December 31, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $471,602K ÷ $140,773K
= 3.35

The current ratio of Corcept Therapeutics Incorporated has exhibited fluctuations over the reported periods. It started at a relatively high level of 10.88 as of March 31, 2020, indicating a strong ability to cover short-term obligations with current assets. The ratio remained elevated through the subsequent quarters of 2020, with values ranging from 10.38 to 10.77.

The ratio then experienced a significant spike to 49.67 by December 31, 2020, suggesting a substantial increase in current assets in relation to current liabilities. This high ratio may indicate a conservative approach to liquidity management or could be reflective of specific financial activities during that period.

Subsequently, the current ratio declined steadily in 2021 and into the first half of 2022, falling to a low of 4.65 by June 30, 2023. This decline may raise concerns about the company's short-term liquidity position or management of current assets and liabilities.

The ratio showed some improvement in the following quarters but remained below the levels seen in the initial periods, ending at 3.35 as of December 31, 2024. Overall, the trend in the current ratio suggests some volatility and fluctuations in Corcept Therapeutics Incorporated's short-term liquidity position over the analyzed period.